This study is in progress, not accepting new patients

Nicotinamide as an Early Alzheimer's Disease Treatment

a study on Alzheimer's Disease Mild Cognitive Impairment Dementia

Summary

Eligibility
for people ages 50 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Joshua Grill

Description

Summary

The purpose of this research study is to test whether nicotinamide, also known as vitamin B3 or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild Alzheimer's disease (AD) dementia.

Official Title

A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia

Details

Nicotinamide, the amide of nicotinic acid (vitamin B3/niacin), is an oral therapy with a wealth of clinical data in a variety of therapeutic areas, including preliminary data supporting its safety in Alzheimer's disease (AD). Preclinical work in a mouse model that develops both plaques and tangles supports the hypothesis that nicotinamide can act as a histone deacetylase (HDAC) inhibitor to reduce phosphorylation of tau. The study will implement a group sequential design, incorporating a futility analysis with a go/no-go decision conditional on cerebral spinal fluid CSF biomarker outcomes at 12-months. The primary outcome for the trial is change in p-tau231. This study timeline includes a screening phase of up to 60 days and treatment phase which is expected to last about 48 weeks and will include 4 study visits. An additional 12-month treatment and follow-up period is planned, contingent upon a "go" decision based on the primary outcome (CSF p-tau231) or one planned secondary outcome (CSF p-tau181)

Keywords

Alzheimer's Disease, Mild Cognitive Impairment, Nicotinamide, Niacinamide, Niacin, Nicotinic Acids, Vitamin, Neurodegenerative Diseases, Tauopathies, Dementia, Alzheimer Disease, Cognitive Dysfunction

Eligibility

You can join if…

Open to people ages 50 years and up

  1. Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease (AD)
  2. Biomarker criteria:

Cerebral Spinal Fluid (CSF) Amyloid Beta 1-42 (Aβ42) <= 600 pg/mL, or A ratio of total tau to Aβ42 ≥ 0.39.

  1. Mini-Mental State Exam (MMSE) ≥ 20
  2. Blood laboratories, urinalysis, and electrocardiogram are within normal limits or deemed clinically not significant by the site investigator
  3. Stable medications (including approved AD therapies) for at least 4 weeks
  4. At least 6 years of education
  5. Able to swallow oral tablets
  6. Speaks English fluently
  7. Available qualified study partner (≥3 times per week in-person communication with the participant)

You CAN'T join if...

  1. Active neurological or psychiatric diagnosis other than AD that may affect cognition and/or function. (Obstructive sleep apnea is permitted, if treated.)
  2. Inability to undergo lumbar puncture, including use of Coumadin, novel oral anticoagulants, clopidogrel, or dipyridamole. Use of aspirin <= 325mg daily is permitted.
  3. Hachinski ischemic scale > 4
  4. Magnetic Resonance Imaging (MRI) incompatibility
  5. MRI evidence of cortical stroke >1cm, superficial siderosis, or extensive white matter hyperintensity (Cardiovascular Health Study score 7-8+)
  6. Diagnosis of cancer in the previous 5 years (with the exception of basal or squamous cell carcinoma)
  7. Geriatric Depression Scale (GDS) score >6
  8. History within the past 5 years of alcohol or substance use disorder
  9. Laboratory evidence of a clinically significant abnormality that may interfere with study assessments
  10. . Active partial or total malabsorptive disease (e.g., celiac disease)
  11. . Resides in a skilled nursing facility
  12. . Participation in a clinical trial of a potential disease-modifying therapy for AD in previous 6-months (time between last investigational drug administration and baseline for the current study)
  13. . Pregnant, lactating or of child bearing potential (that is, women must be 2 years post-menopausal or surgically sterile to be considered not child bearing potential).
  14. . Unwillingness to abstain from over-the-counter nicotinamide for the duration of the trial

Locations

  • University of California, Irvine
    Irvine California 92697 United States
  • University of California, Los Angeles
    Los Angeles California 90095 United States

Lead Scientist at UC Irvine

  • Joshua Grill
    Professor, Psychiatry, School of Medicine. Authored (or co-authored) 82 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Irvine
ID
NCT03061474
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 48 study participants
Last Updated